News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Midwest BioResearch, LLC (MBR) Introduces Industry’s First Screen That Fully Predicts the GLP Regulatory Ames Test


3/19/2007 11:58:48 AM

SKOKIE, Ill.--(BUSINESS WIRE)--Midwest BioResearch, LLC (MBR), an outsourced drug disposition and toxicology contract services provider, today announces the introduction of a novel microAmes screen that fully predicts the GLP regulatory Ames test (Salmonella/E. coli Mammalian Microsome Reverse Mutation Assay). The screen is accurate, rapid, flexible and cost-effective, making it an essential consideration for anyone interested in efficient drug discovery and development through smarter decision making during lead optimization.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES